ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 105.6 | 84.1 | 72.7 |
| Other income | 1.1 | 1.0 | 1.0 |
| Total income | 106.7 | 85.1 | 73.8 |
| Profit before exceptional items & tax | 9.5 | 8.3 | 5.1 |
| Profit before tax | 9.5 | 8.3 | 5.1 |
| Net profit | 6.5 | 5.6 | 3.7 |
| Operating margin | 8.9% | 9.8% | 6.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +75.70% |
|---|---|
| Net profit, quarter on quarter | +16.10% |
| Revenue, year on year | +45.30% |
NSE results filing, NSE: INFINIUM. Figures extracted from the filing.
Infinium Pharmachem Ltd: key numbers
- Share price
- ₹292.50
- Market cap
- ₹407.1 Cr
- Revenue (annual)
- ₹189.6 Cr
- Net profit (annual)
- ₹12.15 Cr
- P/E (TTM)
- 33.5×Sector 43.8×
- Promoter holding
- 64.91%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Infinium Pharmachem Ltd
All →Infinium Pharmachem H1 FY27 Results: Net Profit ₹8.9 Cr, Up 58.9% YoY
Infinium Pharmachem Ltd reported revenue from operations of ₹129.7 Cr (+54.2% YoY) and net profit of ₹8.9 Cr (+58.9% YoY) for H1 FY27.
- Key figure
- Net profit ₹8.9 Cr · +58.9% YoY
Infinium Pharmachem Other Announcement
Infinium Pharmachem Limited filed its quarterly SEBI Regulation 74(5) compliance certificate for the period ending September 30, 2026, confirming all shares are held in demat form.
Infinium Pharmachem SME to Main Board Migration
Infinium Pharmachem Limited submitted its Annual Secretarial Compliance Report for 2026. This filing supports the company's application to migrate from the NSE SME Emerge platform to the Main Board.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited announced that the resolution for migrating its equity shares from the NSE Emerge platform to the mainboard was passed via postal ballot.
Infinium Pharmachem Credit Rating
ICRA assigned a new [ICRA]BBB (Stable) rating to Infinium Pharmachem's ₹52.20 Crore credit facilities. The assignment covers cash credit, term loans, and unallocated limits from ICICI Bank and SBI.
Infinium Pharmachem Annual General Meeting
Infinium Pharmachem Limited held its 22nd Annual General Meeting on September 17, 2026. Shareholders transacted ordinary and special business, including director appointments and remuneration revisions.